⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 18, 2023JAMAOpen Access

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

ClinicalTrials.gov Identifier: NCT02394795.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Watanabe et al. (2023) studied this question.

synapsesocial.com/papers/69dd1c4a7a4feaa6eae52e1e https://doi.org/10.1001/jama.2023.4428

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

1Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancerClinical Guideline · 2017 · 2,472 citations
2Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal CancerLate-Phase Clinical Trial · 2017 · 12 citations